000			01873nam a22002657a 4500
003			OSt
005			20240305193747.0
008			221206b |||||||| |||| 00| 0 eng d
028			_b Phone: +255 28 298 3384
028			_b Fax: +255 28 298 3386
028			_b Email: vc@bugando.ac.tz
028			_b Website: www.bugando.ac.tz
040			_bEnglish _cDLC
041			_aEnglish
100			_aRobert N Peck _922982
222			_a HIV Editorials Immunology Hypertension
245			_aImmunology of hypertension in people with HIV
260			_aMwanza, Tanzania: _b Journal of the American Heart Association & _b Catholic University of Health and Allied Sciences [CUHAS – Bugando] _c2020/2/18
300			_a Pages e015725
490			_v Journal of the American Heart Association Volume 9 Issue 4
520			_aHIV (PWH) are living longer and the leading causes of death in PWH are now cardiovascular disease (CVD), non-AIDS malignancies, and liver disease. 1 The risk of CVD in PWH is 2.5-fold higher than in HIV-uninfected adults, and HIV-associated CVD contributes to 2.6 million disability-associated life-years annually. 2 Hypertension is the leading risk factor for CVD in PWH. Globally, hypertension ranks as the strongest risk factor for CVD and causes> 10 million deaths and 200 million disability-adjusted life-years per year. 3 A recent meta-analysis indicates that the prevalence of hypertension in PWH on ART is 35% and increasing. 4 Data suggest that PWH and concurrent hypertension may experience an even higher risk of CVD than similar hypertensive HIV-negative adults. 5 Novel pathophysiologic mechanisms may drive hypertension in PWH. 6 HIV-specific mechanisms for hypertension may include microbial
700			_a Justin R Kingery _946668
856			_uhttps://doi.org/10.1161/JAHA.120.015725
942			_2ddc _cVM
999			_c19953 _d19953